Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsA trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care
1.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
2.
Could AI plus lasers help catch very early breast cancers?
3.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
4.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
5.
A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.
1.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
2.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
3.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
4.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
5.
Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge